*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2026 | Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · preclinical | PMID 41490200 |
| 2021 | Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke Molecules (Basel, Switzerland) · preclinical | PMID 34500605 |
| 2018 | Phosphorylated delta sleep inducing peptide restores spatial memory and p-CREB expression by improving sleep architecture at high altitude Life sciences · preclinical | PMID 30107169 |
| 2017 | Expression and Purification of Delta Sleep-Inducing Peptide Fused with Protein Transduction Domain and Human Serum Albumin in Pichia pastoris Protein and peptide letters · preclinical | PMID 28462721 |
| 2014 | Delta-sleep inducing peptide entrapment in the charged macroporous matrices Materials science & engineering. C, Materials for biological applications · preclinical | PMID 25063142 |
| 2009 | Delta sleep-inducing peptide and glucocorticoid-induced leucine zipper: potential links between circadian mechanisms and obesity? Obesity reviews : an official journal of the International Association for the Study of Obesity · preclinical | PMID 19849801 |
| 2008 | Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection Neuroscience and behavioral physiology · preclinical | PMID 18975104 |
| 2006 | Delta sleep-inducing peptide (DSIP): a still unresolved riddle Journal of neurochemistry · preclinical | PMID 16539679 |
| 2001 | Delta sleep-inducing peptide European journal of anaesthesiology · preclinical | PMID 11437870 |
| 1994 | Decreased delta-sleep and plasma delta-sleep-inducing peptide in patients with Cushing syndrome Neuroendocrinology · preclinical | PMID 7700506 |
| 1987 | The effects of delta-sleep-inducing peptide (DSIP) on wakefulness and sleep patterns in the cat Brain research · preclinical | PMID 3620931 |
| 1986 | Delta-sleep-inducing peptide (DSIP): an update Peptides · preclinical | PMID 3550726 |
| 1985 | Effects of delta sleep inducing peptide on sleep cycle of cats deprived of paradoxical sleep Archives internationales de physiologie et de biochimie · preclinical | PMID 2421663 |
| 1984 | Delta-sleep-inducing peptide (DSIP): a review Neuroscience and biobehavioral reviews · preclinical | PMID 6145137 |
| 1977 | Characterization of a delta-electroencephalogram (-sleep)-inducing peptide Proceedings of the National Academy of Sciences of the United States of America · preclinical | PMID 265572 |
DSIP (Delta Sleep-Inducing Peptide). Endogenous nonapeptide first isolated from rabbit brain during slow-wave sleep induction. Proposed modulation of sleep architecture, stress/HPA-axis, and pain perception; mechanism remains incompletely characterised.
Commonly discussed uses: sleep support (research/anecdotal), stress modulation. There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Endogenous nonapeptide first isolated from rabbit brain during slow-wave sleep induction. Proposed modulation of sleep architecture, stress/HPA-axis, and pain perception; mechanism remains incompletely characterised.
Reported considerations: limited human data, anecdotal: paradoxical alertness in some, headache. There is both human and animal/preclinical research, though the depth and quality vary by indication. Not approved for human use. Research peptide only. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low 100mcg, typical 100-300mcg pre-sleep, high ~1mg (research). Administration: subcutaneous, intranasal. Half-life: very short (minutes); effects reported longer.
Australian status: Not ARTG-registered; research. Not approved for human use. Research peptide only. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: 2ml BAC water per 5mg vial; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): DSIP + epitalon (sleep/circadian, anecdotal). Stacking increases interaction/safety uncertainty.